Paradigm Biopharmaceuticals is a pharmaceutical company based in Melbourne, Australia, that develops injectable pentosan polysulfate sodium, a medicine it is studying for painful inflammatory conditions. Its main focus is osteoarthritis of the knee, where it aims to reduce pain and improve joint function, and it also explores related uses such as bone marrow oedema and other musculoskeletal and inflammatory disorders. The company works with clinical investigators and regulators to run trials of its formulation, and its customers would ultimately be patients and the clinicians who treat them.
The shares are listed on the Australian Securities Exchange in Australia under the code PAR, and the price on this page is in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Fair price profile
Ranks #707 of 1815 on the Australian Securities Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Australia yet.
TrendFair
69/100
Mixed trend against its averages.
See the numbers →
Above 200-day average8.9%
From 52-week high-45.6%
MomentumStrong
70/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return40.0%
6-month return8.9%
12-month, skipping last month-33.8%
Stability (higher is calmer)Weak
39/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)71.6%
Worst drawdown, 1 year (smaller is calmer)-68.9%
LiquidityFair
51/100
Moderate trading activity.
See the numbers →
Avg daily value traded0.39M AUD
Zero-volume days35.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Australia when fundamentals data for this market is added. All Australia stocks.
52-wk range 0.135 – 0.470Daily closes, split-adjusted
Signals
50-day average0.231
200-day average0.225
Golden/death cross (60d)Golden, 2 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.005
Technical summary
Daily
Bullish
8 bullish · 3 neutral · 3 bearish
Weekly
Bullish
8 bullish · 1 neutral · 3 bearish
Monthly
Bearish
2 bullish · 1 neutral · 5 bearish
Moving averages (daily)
SMA 10
0.25
Bearish
EMA 10
0.25
Bearish
SMA 20
0.25
Bearish
EMA 20
0.24
Bullish
SMA 50
0.23
Bullish
EMA 50
0.23
Bullish
SMA 100
0.20
Bullish
EMA 100
0.22
Bullish
SMA 200
0.22
Bullish
EMA 200
0.23
Bullish
Oscillators (daily)
RSI (14)
56.01
Neutral
MACD (12, 26)
0.00
Bullish
Momentum (12)
0.00
Neutral
Stochastic %K (14)
–
n/a
Williams %R (14)
–
n/a
CCI (20)
-66.67
Neutral
Pivot points (classic, last session)
S3
0.25
S2
0.25
S1
0.25
Pivot
0.25
R1
0.25
R2
0.25
R3
0.25
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in AUD. Educational only, not financial advice.
